LINTONPHARM
1.12.2021 14:02:14 CET | Business Wire | Press release
LintonPharm Co., Ltd., a China-based clinical stage biopharmaceutical company focused on the development of T cell engaging bispecific antibodies for cancer immunotherapy, today announced that the first patient has been dosed in the Company’s Phase 1/2 clinical trial program for catumaxomab (clinicaltrials.gov: NCT04799847 ), a monoclonal bispecific antibody being studied for the treatment of Non-Muscle-Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).
“The initiation of our Phase 1 trial of catumaxomab for the treatment of NMIBC is an important step in our clinical program evaluating catumaxomab as targeted therapy in a broad range of cancers”, said Robert Li, PH.D., DABT, Co-founder and CEO of LintonPharm. “Patients with NMIBC BCG failure need new therapies due to the limitations of current treatments which bring poor prognosis, such as high rates of tumor recurrence, bladder dysfunction and lifelong intervention. Based on encouraging pre-clinical data and clinical experience with patients who’ve received catumaxomab in the past through the compassionate use program, we are hopeful that catumaxomab will be a very promising immunotherapy candidate for patients with NMIBC BCG failure.”
A recent publication indicated clinical benefits of catumaxomab as compassionate use in patients with EpCAM-positive recurrent NMIBC. It is noted that catumaxomab was well tolerated and presented promising performance in tumor control [1] . Based on the data and the developmental potential, catumaxomab could provide a feasible, safe, and efficacious therapy for NMIBC patients, if approved.
Bladder cancer is the 10th most commonly diagnosed cancer worldwide, with approximately 573,000 new cases in 2020 and roughly 75 percent are diagnosed as NMIBC [2][3] . Currently, the mainstay treatments of NMIBC include transurethral resection, chemotherapy and intravesical BCG [3] .
About Catumaxomab
Catumaxomab was approved by the European Medicines Agency in 2009 for the treatment of malignant ascites. This bispecific antibody binds to a transmembrane glycoprotein on the tumor cell--the epithelial cell adhesion molecule (EpCAM)--and CD3 on the T cell, and also recruits immune accessory cells through FcγR binding. Catumaxomab destroys tumor cells by engaging T cell and accessory cell mediated cytotoxicity and has the potential to induce long-term vaccinal effects which has been verified in animal models.
Recently, catumaxomab was authorized by regulatory authorities in China, Taiwan (China) and South Korea to conduct a global Phase 3 clinical trial for treating patients with advanced gastric cancer (clinicaltrials.gov: NCT04222114 ).
About LintonPharm
LintonPharm Co., Ltd. is a clinical-stage, research-oriented biopharmaceutical company committed to developing innovative T cell engaging bispecific antibodies with the goal of turning malignant cancers into manageable and possibly curable diseases. LintonPharm has developed multiple bispecific antibody platforms with a great potential of refined safety and efficacy profiles, long-lasting vaccinal effects and CMC efficiency. The current pipeline includes several treatments in development for blood cancer and solid tumors. The leading molecule, catumaxomab is being evaluated in clinical trials for both advanced gastric cancer and non-muscle invasive bladder cancer. For more information, please visit www.lintonpharm.com .
[1]. Ruf P, Bauer HW, Schoberth A, Kellermann C, Lindhofer H (2021). First time intravesically administered trifunctional antibody catumaxomab in patients with recurrent non muscle invasive bladder cancer indicates high tolerability and local immunological activity. Cancer Immunology, Immunotherapy. http://doi.org/10.1007/s00262-021-02930-7 |
[2]. World Health Organization (WHO). Globocan 2020. Global Cancer Observatory. Accessed January 7, 2021. https://gco.iarc.fr/ |
[3]. Kamat AM, Hahn NM, Efstathiou JA, et al. (2016) Bladder cancer. Lancet 2016. 388: 2796-810. http://dx.doi.org/10.1016/S0140-6736(16)30512-8 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20211201005307/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NEURA Robotics Announces Record Series C of up to $1.4 Billion to Accelerate the World’s Leading Physical AI Platform10.6.2026 17:26:00 CEST | Press release
Landmark investment drives NEURA's open ecosystem, where humanoid and cognitive robots share intelligence and capabilities at scaleBacking from Tether, Qualcomm Technologies, Amazon, NVIDIA, imec.xpand, Bosch, Schaeffler, European Investment Bank, Lingotto Horizon, InterAlpen Partners and others demonstrates global confidence in NEURA’s leadershipNew capital raise is the largest of a full-stack robotics company everCapital will drive serial production to multi-million robots by 2030 and support the global rollout of NEURA Gyms, the world’s first real-world training environments for cognitive robots and Physical AI NEURA Robotics (“NEURA”), the pioneer in cognitive robotics and creator of the Neuraverse, today announced a landmark Series C financing with a total round size of up to $1.4 billion to accelerate its mission of building the world’s leading Physical AI platform. The financing brings together global leaders across AI, robotics, compute, manufacturing and industrial infrastruct
ees Europe: Green Hydrogen: Opportunities and Production Ramp Up10.6.2026 16:13:00 CEST | Press release
For the major economies, the transformation towards a climate-neutral industry is one of the central tasks for the coming decades. While the European Union has pledged climate neutrality by 2050, China’s goal is to be climate-neutral by 2060. Hydrogen is a key to transforming their manufacturing and energy industry. However, the actual market development is lagging behind these ambitious objectives: According to the Global Energy Report 2025, only 11 percent of hydrogen projects announced since the start of the decade are now in operation or have been secured by investment decisions. This is why ees Europe, Europe’s largest and most international exhibition for batteries and energy storage systems, is putting a spotlight on hydrogen. The newly aligned exhibition segment Hydrogen Dialogue Forum & Expo in hall B2 will be giving in-depth information about the opportunities for hydrogen technology, technological innovation, savings potential and ground-breaking projects from June 23–25. Th
Info-Tech Research Group Recognizes Laserfiche as a Champion in the 2026 Enterprise Content Management – Enterprise Emotional Footprint Report10.6.2026 16:00:00 CEST | Press release
Laserfiche has been named a Champion for the enterprise category in the Enterprise Content Management Emotional Footprint 2026 Report by Info-Tech Research Group. Laserfiche — the leading SaaS provider of intelligent content management — was recognized based on reviews provided by end users. Laserfiche was recognized as a Champion for delivering significant business value, continued product innovation, and strong customer experience. “We are honored to be named a Champion by Info-Tech Research Group, which we believe underscores our relationships with our customers and commitment to their long-term success,” said Thomas Phelps, CIO and SVP of corporate strategy at Laserfiche. “We are grateful to our customers for partnering with us as we support their needs for AI-driven information management solutions. Of the 285 customers who completed an Info-Tech survey this year, 99% said they plan to renew.” Info-Tech Research Group’s Emotional Footprint report quantifies the end-user experience
BTG Pactual TIG Acquires Jamestown’s Timberland Platform10.6.2026 15:30:00 CEST | Press release
Acquisition includes approximately 90,000-acre U.S. timberland portfolio BTG Pactual Timberland Investment Group (BTG Pactual TIG), one of the world’s largest timberland investment managers, today announced the acquisition of approximately 90,000 acres of U.S. timberland formerly managed by Jamestown, a global design-focused real estate investment and management firm. The Jamestown timberland platform will be integrated into BTG Pactual TIG’s core U.S. timberland strategy’s portfolio. The portfolio of high-quality timberland spans five U.S. states, including approximately 50,000 acres of pine timberland in Georgia and Alabama and approximately 40,000 acres of diversified hardwood timberland across Indiana, Pennsylvania, and New York. All properties are certified under the Sustainable Forestry Initiative (SFI). The acquisition increases BTG Pactual TIG’s core U.S. timberland strategy’s portfolio to more than 1.7 million acres. The firm manages 3.3 million acres globally. The transaction
Solana Becomes Presenting Sponsor of the World Series of Poker®10.6.2026 15:00:00 CEST | Press release
WSOP to Bring Crypto to Global Events Through Solana-Powered Tournament Ticket Purchases The World Series of Poker (WSOP®), the longest-running and most prestigious poker tournament series in the world, today announced a first-of-its-kind collaboration with the Solana Foundation to bring crypto directly into the global poker experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260610344534/en/ The World Series of Poker TV production set in Las Vegas, presented by Solana Beginning today at the 57th annual summer event at Paris Las Vegas and Horseshoe Las Vegas, players will be able to purchase tournament tickets using Solana, powered by MoonPay’s payment infrastructure. This will be the first time in WSOP history where players can buy tournament tickets directly with crypto, and by leveraging Solana’s technology, this payment method will have zero processing fees. The integration will expand further at the 2026 WSOP Par
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom